Journal of Clinical Oncology· 2012Q1

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell et al.

1,526citations
Q1SCImago
2012year

Short summary

Brentuximab vedotin achieved a 75% objective response rate (ORR), including 34% complete remission (CR), in patients with relapsed or refractory Hodgkin's lymphoma (HL) after autologous stem-cell transplantation (auto-SCT).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pathology and Forensic Medicine

Pathology and Forensic MedicineMedicine